We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Business
Archived
•
October 29, 2026
•
182 views
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Source: CNBC Top | https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



